Funding

Oryon Cell Therapies

United States · Biotech

Develops autologous neuron replacement medicines for Parkinson's disease and other neurodegenerative disorders

Visit oryoncelltherapies.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A$21MByers Capital — Role not disclosedNeuro.VC — Role not disclosed

Investors

Byers CapitalSeries ANeuro.VCSeries A

Coverage

Mar 23, 2026Oryon Cell Therapies · Series A

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesoryoncelltherapies.com ↗